Navigation Links
Principles of CAR T Cell Therapy and the Pathway to Regulatory Approval, Upcoming Webinar Hosted by Xtalks
Date:5/31/2019

For many years, the primary forms of cancer treatment have been chemotherapy, radiation and surgery, but the toughest forms of cancer demand breakthrough therapies. Advances in immuno-oncology have led to the advent of Chimeric Antigen Receptor T (CAR T) cell therapy, which combines a patient’s own T cells with engineered T cell receptors known as “CARs”. The CAR enables the final product to produce chemicals in the hopes that the “enhanced” product or cells will bind to the cancer cells and kill them.

The industry has seen successes in using CAR T therapy in several blood cancers, including acute myeloid leukemia, acute lymphoblastic leukemia and lymphoma. Some of these unique therapies have already been cleared by the US Food and Drug Administration (FDA), but the pathway to the clinic comes with several challenges.

Join Brian D. Marks, BSc, DC, Senior Director, Project Delivery, Oncology at Premier Research and Ashley Jones, MSc, Project Lead, Project Management, Oncology at Premier Research in a live webinar on Tuesday, June 18, 2019 at 11am EDT (4pm BST/UK) to learn about:

  •     Principles of CAR-T cell therapy
  •     FDA-approved CAR-T cell therapies
  •     Operational and clinical pathways that bring CAR-T cell therapies to patients
  •     Challenges with clinical application

For more information or to register for the complimentary session, visit Principles of CAR T Cell Therapy and the Pathway to Regulatory Approval.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:
Candice Tang
Tel: +1 (416) 977-6555 ext 400
Email: ctang@xtalks.com

Read the full story at https://www.prweb.com/releases/principles_of_car_t_cell_therapy_and_the_pathway_to_regulatory_approval_upcoming_webinar_hosted_by_xtalks/prweb16340590.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. Investors Applaud Amgen and Novartis for Support of Investor Principles on Biosimilars, Alternatives to Higher Cost Drugs
2. Chemical Publishing Company to Release New Title Boiler Water Treatment Principles and Practice: Charts and Notes for Field Use
3. VetStem Biopharma Shares the Story of Atlas Who Was Successfully Treated with VetStem Cell Therapy by Dr. Colter Negranti
4. VetStem Biopharma Shares the Success Story of Frank who was Treated with VetStem Cell Therapy by Pain Management Specialist Dr. Jamie Gaynor
5. VetStem Biopharma Shares the Story of Sonny Bar Lisa Who Was Successfully Treated With VetStem Cell Therapy
6. ASGCT Members Elect Five New Directors from CHOP, UMass, Advanced Therapy Partners, bluebird bio, and Vanderbilt University
7. VetStem Regenerative Cell Therapy Helps Arthritic Sun Bear at the World-Famous San Diego Zoo
8. VetStem Biopharma is Pleased to Share the Success Story of Bogey Who Was Treated with VetStem Cell Therapy by Dr. Ava DeCozio
9. Sheba Medical Center to Collaborate with Lonza Pharma on State-of-the-Art "Cocoon" Platform to Aid Cancer Patients' Access to Life-Saving CAR-T Immunotherapy Treatments
10. VetStem Biopharma Shares the Story of San Fransisko Who Advanced in His Dressage Career After Being Treated with VetStem Cell Therapy
11. AskBio Announces First Patient Dosed with Gene Therapy in Phase 1/2 Study of ACTUS-101 in Patients with Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2019)... ... ... For many years, the primary forms of cancer treatment have been chemotherapy, radiation and ... led to the advent of Chimeric Antigen Receptor T (CAR T) cell therapy, which ... The CAR enables the final product to produce chemicals in the hopes that the ...
(Date:5/31/2019)... ... May 30, 2019 , ... A ... an efficient delivery system for the sustained release of human placental stem cell ... system was able to deliver CM into the injured kidney, where it helped ...
(Date:5/15/2019)... ... May 16, 2019 , ... Emulsifiers are ... food and beverage products rely on these ingredients to create stable quality food ... declarations. This paradigm shift triggers food formulators to seek out alternatives for starches, ...
(Date:5/7/2019)... ... May 06, 2019 , ... "The ... growing number of repositories being asked to store cellular products being used ... of contributors who are world leaders, who have shared their expertise in building ...
Breaking Biology Technology:
(Date:6/16/2019)... (PRWEB) , ... June 14, 2019 , ... ... Americans invited to lecture at the fifth annual Neodent World Congress. Attended by ... the innovative progress and latest advancements in the world of dentistry. The three-day ...
(Date:6/13/2019)... , ... June 13, 2019 , ... ... the first organization exclusively serving the end-to-end clinical and ancillary supply chain management ... as contract and medical research organizations, today announced it will sponsor a summer ...
(Date:6/6/2019)... ... June 05, 2019 , ... Pelican BioThermal , ... station and service center in Mexico City, Mexico. Mexico is the second largest ... more than $1.75 billion in pharmaceutical exports since 2015. The Mexico City network ...
Breaking Biology News(10 mins):